Drug
Dtx101
Dtx101: highest development phase Phase 1/2, developed by Ultragenyx Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| DTX101 NCT02618915 | Phase 1/2 | Hemophilia B |
Latest
No recent events.
Follow Dtx101 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.